Abbott laboratories (ABT)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Mar'11Dec'10Sep'10Jun'10Mar'10Dec'09Sep'09Jun'09Mar'09Sep'08Jun'08
Net sales

7,726

8,314

8,076

7,979

7,535

7,765

7,656

7,767

7,390

7,589

6,829

6,637

6,335

5,333

5,302

5,333

4,885

5,188

5,150

5,170

4,897

5,356

5,079

5,057

4,755

4,008

4,825

5,446

5,378

3,188

5,264

5,313

5,283

-7,066

9,816

9,616

9,040

9,967

8,674

8,826

7,698

8,790

7,761

7,494

6,718

7,497

7,314

Cost of products sold, excluding amortization of intangible assets

3,281

3,434

3,358

3,279

3,160

3,191

3,166

3,282

3,067

3,282

2,876

3,189

3,062

2,382

2,285

2,287

2,140

2,206

2,242

2,218

2,081

2,337

2,319

2,288

2,274

1,961

2,255

2,545

2,432

1,680

2,488

2,370

2,359

-1,685

3,973

3,870

3,858

4,045

3,741

3,543

3,335

3,784

3,360

3,128

2,935

3,352

3,119

Amortization of intangible assets

561

483

484

483

486

488

544

562

584

560

501

392

522

121

140

145

144

143

151

151

156

163

132

133

127

46

146

197

199

-4

195

194

209

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Research and development

578

595

596

577

672

562

574

575

589

619

568

520

553

368

352

348

379

369

378

345

313

361

305

310

369

323

339

363

346

376

350

370

363

-1,465

1,009

1,037

930

1,057

1,078

857

730

747

675

670

650

680

656

Acquired in-process and collaborations research and development

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

172

100

-

-

75

-

-

-

-

-

-

78

Selling, general and administrative

2,548

2,413

2,440

2,434

2,478

2,359

2,377

2,466

2,542

2,477

2,115

2,150

2,440

1,673

1,628

1,737

1,698

1,655

1,666

1,727

1,737

1,666

1,595

1,649

1,620

1,260

1,612

1,714

1,786

1,159

1,920

1,813

1,842

-2,486

4,238

2,762

2,850

2,797

2,673

2,743

2,162

2,225

2,085

2,024

2,070

2,067

2,052

Total operating cost and expenses

6,968

6,925

6,878

6,773

6,796

6,600

6,661

6,885

6,782

6,938

6,060

6,251

6,577

4,544

4,405

4,517

4,361

4,373

4,437

4,441

4,287

4,527

4,351

4,380

4,390

3,590

4,352

4,819

4,763

3,211

4,954

4,749

4,774

-5,026

9,221

7,842

7,739

8,137

7,493

7,220

6,227

6,926

6,121

5,823

5,657

6,101

5,907

Operating earnings

758

1,389

1,198

1,206

739

1,165

995

882

608

651

769

386

-242

789

897

816

524

815

713

729

610

829

728

677

365

418

473

627

615

-23

310

564

509

-2,040

594

1,773

1,301

1,829

1,181

1,605

1,470

1,863

1,639

1,671

1,060

1,396

1,406

Interest expense

139

164

167

168

171

186

203

210

227

246

218

214

226

153

117

103

58

41

41

44

37

43

35

36

36

27

37

40

41

2

152

83

82

-45

124

134

145

151

149

134

118

123

134

136

124

125

137

Interest (income)

18

25

24

22

23

34

22

21

28

35

36

31

22

24

22

20

33

32

25

27

21

24

18

19

16

19

16

17

15

-40

63

18

16

3

20

18

21

22

15

38

29

29

38

33

36

55

54

(Income) from the TAP Pharmaceutical Products Inc. joint venture

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

17

Net foreign exchange (gain) loss

-5

2

-7

4

-6

-26

-11

6

3

0

6

12

16

2

-9

-10

-478

30

14

-5

54

24

1

0

-1

-8

2

-11

-29

9

12

24

-14

-28

5

10

32

19

20

40

-70

-6

-0

-14

-14

-17

-14

Debt extinguishment costs

-

-

-

-

-

-86

-67

0

-14

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other (income) expense, net

1

51

55

38

47

46

-18

78

33

134

33

80

1,166

213

-972

-8

-19

-6

3

279

5

-12

3

-2

-3

3

27

8

-6

-36

-2

5

34

11

5

5

-140

47

-4

8

10

60

327

13

974

63

310

Earnings from continuing operations before taxes

633

1,240

1,103

1,102

632

947

718

777

431

574

626

295

736

875

-179

715

2

830

714

986

653

804

715

658

341

405

481

601

554

-1,444

231

529

463

-2,008

501

1,674

1,068

1,767

1,064

1,558

1,322

1,822

1,871

1,567

1,932

1,373

1,636

Tax expense (benefit) on earnings from continuing operations

89

191

143

96

-40

292

166

59

22

1,438

65

25

350

110

178

116

-54

135

118

200

124

170

277

233

117

81

-163

125

10

-580

-107

118

112

-25

198

-268

204

326

173

267

319

284

391

278

493

288

314

Earnings from continuing operations

544

1,049

960

1,006

672

655

552

718

409

-864

561

270

386

765

-357

599

56

695

596

786

529

634

438

425

224

324

644

476

544

-863

338

410

351

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Earnings from discontinued operations, net of tax

20

-

-

-

-

-1

11

15

9

-

42

13

-

33

28

16

260

72

-16

-2

1,763

-

100

41

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Earnings from Discontinued Operations, net of taxes

-

-

-

-

-

-

-

-

-

-

-

-

33

33

28

16

244

-

-32

-

-

271

100

41

151

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Earnings (loss) from discontinued operations, net of tax

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-1

26

-

-

-

151

-

322

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Gain on sale of Discontinued Operations, net of taxes

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

16

0

16

-1

1,737

-

-

-

-

-

-

-

-

-

1,603

1,313

890

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net Earnings

564

1,049

960

1,006

672

654

563

733

418

-828

603

283

419

798

-329

615

316

767

580

784

2,292

905

538

466

375

590

966

476

544

1,053

1,942

1,724

1,242

1,618

303

1,942

863

1,440

890

1,291

1,003

1,538

1,480

1,288

1,438

1,084

1,322

Basic Earnings Per Common Share
Continuing operations (in dollars per share)

0.31

0.58

0.54

0.57

0.38

0.37

0.31

0.41

0.23

-0.49

0.32

0.15

0.22

0.51

-0.24

0.40

0.04

0.46

0.40

0.52

0.35

0.42

0.29

0.28

0.14

0.21

0.41

0.30

0.35

-0.54

0.21

0.26

0.22

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Discontinued operations (in dollars per share)

0.01

-

-

-

-

-0.01

0.01

0.01

0.01

0.02

0.02

0.01

0.02

0.03

0.02

0.01

0.17

0.05

-0.01

0.00

1.17

0.17

0.07

0.03

0.10

-

0.21

-

-

1.20

1.01

0.83

0.57

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net earnings (in dollars per share)

0.32

0.58

0.54

0.57

0.38

0.36

0.32

0.42

0.24

-0.47

0.34

0.16

0.24

0.54

-0.22

0.41

0.21

0.51

0.39

0.52

1.52

0.59

0.36

0.31

0.24

0.37

0.62

0.30

0.35

0.66

1.22

1.09

0.79

1.04

0.19

1.24

0.56

0.92

0.58

0.83

0.65

1.00

0.95

0.83

0.93

0.70

0.86

Diluted Earnings Per Common Share
Continuing operations (in dollars per share)

0.30

0.59

0.53

0.56

0.38

0.37

0.31

0.40

0.23

-0.49

0.32

0.15

0.22

0.51

-0.24

0.40

0.04

0.46

0.39

0.52

0.35

0.41

0.29

0.28

0.14

0.21

0.41

0.30

0.34

-0.54

0.21

0.26

0.22

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Discontinued operations (in dollars per share)

0.01

-

-

-

-

-

0.01

0.01

-

0.02

0.02

0.01

0.02

0.03

0.02

0.01

0.17

0.05

-0.01

0.00

1.16

0.18

0.07

0.02

0.10

-

0.20

-

-

1.19

1.00

0.82

0.56

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net earnings (in dollars per share)

0.31

0.59

0.53

0.56

0.38

0.37

0.32

0.41

0.23

-0.47

0.34

0.16

0.24

0.54

-0.22

0.41

0.21

0.51

0.38

0.52

1.51

0.59

0.36

0.30

0.24

0.37

0.61

0.30

0.34

0.65

1.21

1.08

0.78

1.04

0.19

1.23

0.55

0.92

0.57

0.83

0.64

0.99

0.95

0.83

0.92

0.69

0.85

Cash Dividends Declared Per Common Share (in dollars per share)

-

-

-

-

-

-

-

-

-

-

0.26

0.26

0.26

-

0.26

0.26

0.26

-

0.24

0.24

0.24

-

0.22

0.22

0.22

-

0.14

0.14

0.14

-

0.51

0.51

0.51

-

0.48

0.48

0.48

-

0.44

0.44

0.44

-

0.40

0.40

0.40

0.36

0.36

Average Number of Common Shares Outstanding Used for Basic Earnings Per Common Share (in shares)

1,768

1,768

1,771

1,768

1,763

1,761

1,759

1,757

1,753

1,748

1,743

1,740

1,727

1,479

1,476

1,474

1,477

1,489

1,495

1,493

1,504

1,515

1,508

1,506

1,532

1,550

1,551

1,560

1,568

1,577

1,576

1,572

1,573

1,560

1,558

1,556

1,551

1,547

1,545

1,544

1,547

1,550

1,546

1,545

1,545

1,545

1,539

Dilutive Common Stock Options (in shares)

11

13

12

12

13

12

12

11

11

9

10

8

7

5

6

5

6

9

9

10

10

7

11

10

14

15

14

16

17

18

17

16

15

14

9

9

6

8

8

7

13

10

6

4

10

18

13

Average Number of Common Shares Outstanding Plus Dilutive Common Stock Options (in shares)

1,780

1,781

1,784

1,781

1,776

1,774

1,771

1,768

1,765

1,757

1,754

1,748

1,735

1,491

1,476

1,480

1,483

1,499

1,505

1,504

1,515

1,523

1,519

1,517

1,547

1,566

1,566

1,576

1,586

1,595

1,594

1,588

1,589

1,574

1,568

1,566

1,558

1,556

1,554

1,551

1,561

1,561

1,552

1,550

1,556

1,563

1,553

Outstanding Common Stock Options Having No Dilutive Effect (in shares)

4

239

0

0

4

-

0

0

-

-

0

5

9

-3

12

5

5

-2

0

0

5

-1

0

0

4

-4

1

1

5

-1

1

1

3

-77

61

60

63

-44

66

66

29

23

83

90

67

3

48